Core Viewpoint - Sanofi announced that the Phase III COAST 1 study of Amlitelimab for the treatment of atopic dermatitis has met all primary and secondary endpoints [1] Group 1: Drug Information - Amlitelimab is a fully human non-T cell depleting monoclonal antibody targeting OX40L, developed by Sanofi [1] - The drug works by blocking the interaction between the key immune regulatory factor OX40L and its receptor OX40, maintaining the balance between pro-inflammatory T cells and regulatory T cells [1] - Amlitelimab is currently the only OX40L antibody in Phase III development [1] Group 2: Therapeutic Applications - The drug is intended for the treatment of a range of immune and inflammatory diseases, including atopic dermatitis, asthma, and hidradenitis suppurativa [1]